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Abstract
Study design This is a focused review article.
Objectives This review presents important features of clinical outcomes assessments (COAs) in human spinal cord injury
research. Considerations for COAs by trial phase and International Classiﬁcation of Functioning, Disability and Health are
presented as well as strengths and recommendations for upper extremity COAs for research. Clinical trial tools and designs
to address recruitment challenges are identiﬁed.
Methods The methods include a summary of topics discussed during a two-day workshop, conceptual discussion of upper
extremity COAs and additional focused literature review.
Results COAs must be appropriate to trial phase and particularly in mid-late-phase trials, should reﬂect recovery vs. compensation,
as well as being clinically meaningful. The impact and extent of upper vs. lower motoneuron disease should be considered, as this
may affect how an individual may respond to a given therapeutic. For trials with broad inclusion criteria, the content of COAs
should cover all severities and levels of SCI. Speciﬁc measures to assess upper extremity function as well as more comprehensive
COAs are under development. In addition to appropriate use of COAs, methods to increase recruitment, such as adaptive trial
designs and prognostic modeling to prospectively stratify heterogeneous populations into appropriate cohorts should be considered.
Conclusions With an increasing number of clinical trials focusing on improving upper extremity function, it is essential to
consider a range of factors when choosing a COA.
Sponsors Craig H. Neilsen Foundation, Spinal Cord Outcomes Partnership Endeavor.
Introduction
As of 2016, more than half of all spinal cord injuries (SCI),
~58%, affect the cervical spine resulting in tetraplegia and
less than 1% of people with SCI experience complete
recovery by hospital discharge [1]. In persons with tetra-
plegia, upper extremity (UE) function is affected. Initial
human trials of high-risk drug or cell-based interventions
are typically tested in individuals with thoracic SCI fol-
lowed by cervical SCI trials. Trials in thoracic SCI are
conducted to establish safety, as the potential loss of func-
tion in thoracic SCI has less impact than loss of cervical
segments. However, evidence of efﬁcacy is difﬁcult to
assess in the thoracic spine as the standard SCI motor exam
(International Standards for Neurological Classiﬁcation—
ISNCSCI) defers to segmental sensory assessments, as
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accurate testing using the ISNCSCI motor scoring system is
only available for muscles of the extremities [2]. In contrast,
muscles in the UE innervated by cervical segments are
readily testable, thus efﬁcacy assessed by motor function is
easier to detect.
Restoration of UE function is consistently identiﬁed as
one of the top priorities for individuals living with tetra-
plegia [3]. Neurological improvement within cervical cord
segments resulting in functional change has the potential to
signiﬁcantly impact quality of life, as regaining function of
even one cervical level can make the difference between
independence and dependence for many ADLs such as
transfers and self-care [4]. Loss of UE function impacts
other activities, which are also top priorities for individuals
with SCI, such as ability to manage one’s own bowel and
bladder program. Due to the readily testable motor function
in the UE and the importance of UE function, pivotal
(conﬁrmatory) SCI trials (a study intended to provide
deﬁnitive evidence of efﬁcacy prior to drug marketing
approval) will likely be conducted in persons living with
cervical SCI. In fact, based on data extracted from Clin-
icalTrials.gov between 2012 and 2016, there was an
increase of 22% (from 13 to 35%) of drug, cell, or surgical
interventions using UE clinical outcome assessments
(COAs).
The types of tasks performed with the arm and hand are
complex and diverse. Measures of sensation and strength
(such as those assessed by ISNCSCI) are important, but do
not capture this diversity or directly measure clinically
meaningful function. UE tasks are often asymmetrical,
temporally and spatially varied, with many functional goals
and degrees of freedom. For example, multiple grasp pat-
terns are used during ADLs, ranging from power grasp,
where large forces are required to lift a glass or use a knife,
to prehension tasks, which require precision to pick up a pin
or hold a pencil. In order to capture this diversity, UE COAs
may also be complex. Simple measures of time to complete
a given task, such as those used for speed of gait in the
lower extremity, may provide valuable information, but
speed of performance is only one aspect of function. Thus,
more comprehensive assessments are needed to characterize
UE function.
As a direct result of the increase in trials that include UE
function as an end point, and the lack of consensus on
which UE COAs are best suited for clinical trials, a work-
shop was convened in January 2015 by the Craig H. Neilsen
Foundation (www.chnfoundation.org) in association with
the Spinal Cord Outcomes Partnership Endeavor (www.
scope-sci.org). The goal of this workshop was to assemble
leading experts (predominantly from North America—
Appendix 1) in SCI, UE COAs, and SCI clinical trials, to
identify important concepts in COA and provide guidance
on how emerging and existing measures may be used to
assess experimental therapies in SCI. An additional goal
was to examine methods to facilitate recruitment strategies
for future trials. The focus was on UE COAs assessing
impairment and/or function, in individuals with cervical
complete and incomplete SCI in Phase II–III trials, where
the therapeutic intervention was directed to alter a central
nervous system target. This manuscript highlights key
recommendations based on the expertise of the workshop
participants, the concepts that led to those recommenda-
tions, and additional focused literature review of themes
central to the workshop topics.
Key concepts
Four major areas are discussed herein: (1) Deﬁne important
considerations of COAs; (2) Compare features of select UE
COAs; (3) Discuss broad functional assessment scales that
may allow for more inclusive trial designs and; (4) Deﬁne
remaining gaps and options to address recruitment.
Important features of clinical outcome assessments
Beyond reliability, validity, and responsiveness of a COA
tool, there are numerous factors that are important to con-
sider in the choice of speciﬁc COAs for a given trial.
Considerations include trial phase and measurement target,
whether the COA is able to distinguish between recovery
and compensation, the impact of lower motor neuron injury,
clinical signiﬁcance of the observed changes, gaps in con-
tent, and ﬂoor and ceiling effects. Although the topics dis-
cussed focus on different aspects of COAs for clinical trials,
they are important to consider in aggregate. The choice of
primary outcomes and end points should be driven by the
therapeutic target of the intervention and clinical trial phase.
Table 1 highlights clinical trial phases with associated
relevant measurement domains. In addition to referencing
traditional drug trial phases, we use the terms “early, mid,
and late” phase to encompass trials that may not follow the
drug and biologics path, but may focus on rehabilitative
interventions or devices. Measurement domains are based
on the International Classiﬁcation of Functioning, Disability
and Health (ICF) terminology [5]. The ICF provides a
comprehensive framework for health-related function with
interactions between the health condition (disorder or dis-
ease), body structures and function (impairment), activities
(function) and participation. As COAs are considered along
the ICF spectrum toward activities and participation, the
number of factors that can inﬂuence outcomes increases. At
the body function and structure level (impairment), anato-
mical and physiological variables are assessed and inﬂu-
enced by central nervous system integrity (sensory/motor
neural circuits). In contrast, at the participation levels, more
L. A. T. Jones et al.
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Considerations and recommendations for selection
factors play a role including personal and social character-
istics (e.g., choice, motivation, and social background), as
well as environmental factors (e.g., physical, social, and
attitudinal conditions). Typically, early phase trial outcomes
focus on safety at the base level of the ICF domains (neu-
rological impairment), whereas later stage trials focus on
changes in function needed to accomplish ADLs, and pos-
sibly participation within the community. However, it is
important to establish the link between impairment and
function in mid and late-phase trials. Assessing neurological
impairment alone is a proxy measure and provides no direct
information about the impact of change on functional ability
and thus clinical meaningfulness. Conversely, assessments
that focus solely on the ability to execute select tasks may
capture behavioral compensation as opposed to actual
recovery of functional neural circuitry.
Drug and biological interventions typically target neu-
rological recovery vs. compensation, thus it is important to
deﬁne these terms and choose COAs that reﬂect recovery.
Levin et al. [6] considered recovery vs. compensation at
different structural levels in relation to stroke. Although the
terminology used by these authors was intended to follow
the ICF, they used these terms differently than they are
typically used in SCI, therefore we have simpliﬁed the
terminology herein. At the physiological level, recovery
may occur through neuroplasticity, or repair of injured
neural circuits, whereas compensation may occur by acti-
vation of alternative pathways. At the level of task execu-
tion, recovery is attained by the completion of a movement
in the same manner in which it was accomplished prior to
injury, whereas compensation reﬂects performance of a
previous task with a novel adaptive behavioral strategy. The
movement may be slower, or coordinated by different pat-
terns of muscle activation such as a tenodesis grasp pattern
(passive hand grasp and release mechanism, occurring by
active wrist extension or passive wrist ﬂexion). At the level
of task outcome, true functional recovery is demonstrated
with concomitant improvement in neurological restitution
and correlated with the normal activation of the same limb
or muscles. Conversely, compensation is achieved using
different joints or muscles; for example, opening a bag of
chips with one hand and the mouth instead of two hands.
For mid-late-phase drug or biologics studies COAs should,
to some degree, reﬂect attainment of pre-injury motor
behaviors at the level of task execution and outcome at the
activity level in the ICF classiﬁcation.
Although the impact of recovery and compensation can
be discussed separately, they do not occur in isolation. They
may occur together and inﬂuence one another, both at
physiological and functional levels. However, the distinc-
tion between recovery and behavioral compensation is
important in the context of clinical trials as behavioral
compensation can result from rehabilitation or other
strategies that do not reﬂect the therapeutic effect being
tested. If a clinical trial is using functional electrical sti-
mulation to increase strength and coordination of movement
to achieve a more normal grasp pattern, simply assessing
time to accomplish the task does not necessarily reﬂect the
target of the intervention. One may use a completely dif-
ferent strategy (function) resulting in increased speed,
without commensurate changes at the underlying neurolo-
gical level (impairment), in this case, strength and
coordination.
An example of a COA that focuses on function, but does
not necessarily distinguish between behavioral compensa-
tion and recovery, is the spinal cord independence measure
(SCIM). SCIM III measures aspects of self-care, respiration,
and mobility at the activity level, but does not measure
changes in body structure (neurological impairment)
resulting in improved activity. Curt et al. [7] examined the
contributions of compensation, neural plasticity, and repair
based on neurological assessment of motor function
(ISNCSCI), functional assessments (SCIM and Walking
Index for Spinal Cord Injury II), and electrophysiological
recordings, respectively. In individuals with a motor com-
plete injury, a change in motor score was not correlated with
a change in SCIM. In individuals with motor incomplete
injury, there was a moderate relationship. Thus, in this
study, SCIM did not differentiate recovery from behavioral
compensation. In contrast, a study by Rudhe et al. [8] found
strong correlations between SCIM III self-care and UE
motor scores. Other tools, such as the neuromuscular
recovery scale (NRS) intend to assess an individual’s
capacity without compensation by grading movements in
relation to pre-injury movement patterns [9]. The NRS is
still in the development stage, with the recent addition of
three UE tasks, thus further validation is required to conﬁrm
that it is capturing recovery in the absence of compensation
[10]. Although it is not possible to clearly separate con-
tributions of recovery and compensation with most COAs, it
is important to correlate the contribution of neurological
improvement to a change in functional recovery in the
clinical trial setting.
When interpreting the outcomes of a given intervention,
one needs to consider the contribution of upper motoneuron
(UMN) and lower motoneuron (LMN) lesions. The extent
of LMN damage may vary by level and severity of injury
and across individuals with similar levels of injury. Mul-
cahey et al. [11] found that in children and youths with
C1–C4 injuries, between 2% (triceps) and 91% (biceps
complex) of tested muscles did not respond to stimulation
using surface electrical stimulation, indicating signiﬁcant
LMN damage. Curt et al. [12] found a high rate of sig-
niﬁcant denervation in median and ulnar nerves in indivi-
duals with lower (C6–T1) cervical vs. mid (C4,5) injuries.
These two studies illustrate the prevalence of LMN damage,
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both at the site of injury and one-to-two levels below the
injury. LMN changes may occur from actual traumatic loss
of motoneurons, severe proximal ventral root injury, or
changes in motor unit properties as a result of denervation
(motoneuron sprouting with enlarged motor units). Lower
motoneuron dysfunction is also associated with other seg-
mental neuronal loss, including interneurons that coordinate
activity across motoneuron pools and damage to dorsal
roots and/or sensory processing in the dorsal horn. The
functional impact of LMN loss varies based on the extent of
loss at single and multiple segments. LMN injury is
important to assess as this may have a signiﬁcant impact on
response rate for therapeutics targeting central nervous
system (UMN) dysfunction. Clinically, muscular atrophy
and associated hyporeﬂexia are signs of LMN injury,
whereas spasticity and associated hyperreﬂexia are signs of
UMN injury. However, they can often be seen in combi-
nation after cervical SCI. Surface electrical stimulation may
be used as an initial assessment; peripheral nerve stimula-
tion of muscles impacted by LMN damage commonly
requires more current or may not be excitable. Additional
electro-diagnostic testing (F waves, H reﬂexes) may follow
as needed to provide additional information about LMN
patency [13]. Results of these tests should be considered in
the overall interpretation of results when looking at
responders vs. non-responders to a given therapeutic
approach.
The impact of an intervention in any late-stage clinical
trial should be clinically meaningful (how a person feels,
functions, or survives) to persons with the condition under
study. In successful interventional SCI trials, clinical
meaningfulness of an observed functional effect must be
demonstrated. One way that clinical meaningfulness is
determined is by establishing the minimal clinically
important difference (MCID). While deﬁnitions may vary,
MCID has traditionally been deﬁned as “the smallest dif-
ference in score, within the domain of interest, which
patients perceive as beneﬁcial and which would mandate, in
the absence of troublesome side effects and excessive costs,
a change in the patient’s management” [14]. As MCID may
be expressed as either an improvement or a deterioration,
Hart et al. [15] further separates MCID to reﬂect the
“minimal clinically important improvement” (MCII). Both
MCID and MCII may be impacted by baseline assessment
scores, which vary widely by level and severity of SCI, as
well as demographic characteristics such as age and possi-
bly gender. For example, for individuals with orthopedic
knee impairments, Wang et al. [16] assessed MCII for the
lower extremity functional scale, a computer adaptive
patient-reported outcome (PRO). They found that younger,
male participants and those with more acute symptoms
required a greater change in performance for a measure to
be judged clinically meaningful when compared to older
females or less severely injured subjects. Therefore, it is
difﬁcult to establish a universally accepted MCII or MCID
threshold for any given COA. As discussed by Wu et al.
[17], there are numerous methods to establish MCID but
ideally MCID is established from utilization of a COA in a
clinical trial setting. As few late-phase SCI trials have been
completed, there are very few established MCIDs for SCI
measures. In the absence of an established MCID, the
MCID for a given COA can also be assessed in mid-phase
feasibility studies, prior to use in a pivotal trial.
Beyond measuring meaningful change, COAs
should also be sensitive to change in all severities of injury,
without gaps in content, and without ﬂoor or ceiling effects.
Gaps in content occur when discrete but clinically important
skills are not captured in a COA. Gaps may be present in the
upper and/or lower end of a COA, resulting in ﬂoor and
ceiling effects, respectively, but may occur anywhere along
a scale, resulting in the inability to track important but
discrete aspects of function. Floor effects are present when
the lower levels of an outcome measure may be too difﬁcult,
thus scores are clustered at the lower range and do not
differentiate lower levels of performance. Ceiling effects
occur when the upper levels of a COA can no longer
distinguish or track additional performance improvement.
Many of the existing ordinal COAs such as ISNCSCI, and
SCIM III may not adequately track the extent of recovery
in less severe cases of SCI, for example, individuals with an
American Spinal Injury Association (ASIA) impairment
scale D or “AIS D” classiﬁcation [2]. People with injuries
classiﬁed as AIS D can perform many of the existing items
within the available ordinal COAs over the ﬁrst few months
after injury while continued improvements may not be
captured by these COAs. Because of their extensive func-
tional recovery, and the safety concerns associated with
novel drugs or cell transplants, AIS D participants are rarely
recruited to drug and cell-based SCI studies. Until valida-
tion of existing tools for individuals with AIS D occurs and
the tools are found to be sensitive to small change in
function, it is recommended that recruitment of these indi-
viduals in clinical trials be undertaken cautiously. In order
to expand inclusion criteria to participants with less severe
SCI, assessment tools must be expanded to be sensitive to
improvement at high levels of function.
In summary, when planning a clinical trial, investigators
should ask the following questions when choosing a COA:
1. Is the COA appropriate for the trial phase? Mid- and
late-phase trials should include measures of both
impairment and function.
2. What is the impact of UMN vs. LMN dysfunction on
the interpretation of the COA and response to a given
therapeutic?
3. If the intended population encompasses individuals
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with injuries ranging from thoracolumbar to cervical
injuries, are the COAs sensitive to change in all
severities and levels of SCI?
4. Are the outcomes clinically meaningful? Statistically
signiﬁcant change that is not clinically meaningful
will not support regulatory registration of an investi-
gational product.
Features of select emerging UE clinical outcome
assessments
A number of established instruments and others in devel-
opment that are available for UE assessment, such as those
recently included in the National Institutes of Neurological
Disorders and Stroke Common Data Elements for SCI
research, were discussed at the workshop [18]. These tools
were developed for different uses, including classiﬁcation,
monitoring of clinical improvement, and utilization in
clinical trials. Additionally, they span the range from
assessment of impairments, such as strength and sensation,
to capacity and performance. Measures of capacity are
commonly observed by a health care team in the hospital or
clinical setting. Measures of performance may also be
observed by a member of the health care team in the home
environment, but are commonly assessed by the patient, as a
PRO. While performance is more important to an indivi-
dual, measures of performance collected by PRO do not
differentiate recovery from compensation and, therefore, are
likely to be used as secondary or exploratory clinical trial
end points (vs. primary). Measures of capacity are more
likely to be chosen as primary outcome measures, as it is
possible (with some COAs) to consider the contribution of
compensatory techniques. Table 2 summarizes strengths
and recommendations for use of selected COAs to assess
UE impairment and/or function in clinical trials.
Two COAs that are speciﬁc to UE function after SCI are
under development to provide improved sensitivity to
change in the cervical SCI population, relative to more
“global” activity measures such as SCIM III. The graded
reﬁned assessment of strength, sensibility and prehension
(GRASSP) and capabilities of upper extremities test (CUE-
T) both measure capacity of UE function, but use different
approaches [19, 20]. The GRASSP is multidimensional,
with separate scales for sensation, motor, and prehensile
hand abilities. The CUE-T is unidimensional, with sub-
scales for right/left arm and right/left hand. The CUE-T
contains elements that assess proximal arm function in
addition to hand function, while the GRASSP focuses only
on hand function. Both instruments use standardized objects
and methods to assess the typical grasp patterns (e.g.,
cylindrical grasp, lateral key grip, and tip-to-tip pinch). The
GRASSP allows for the use of compensatory strategies for
prehension but gives a lower score when compensation is
identiﬁed. The CUE-T does not permit alternative grasp
patterns for a particular task. While CUE-T is at an earlier
stage of development, establishment of psychometric
properties for both measures is underway, with more psy-
chometric data currently available on the GRASSP [19–25].
Both measures are being used as secondary COAs in clin-
ical trials.
Emerging functional assessment scales to support
inclusive trials
For clinical trials involving a broad range of subjects, e.g.,
those with different levels and severities of SCI, assessment
of upper and lower extremity function may be indicated,
thus a more “global” COA may be useful. Although there
are several COAs that have been developed speciﬁcally for
SCI, two new tools have broad application across different
types of SCI: The spinal cord injury-functional index (SCI-
FI) and spinal cord ability ruler (SCAR). Although neither
tool is UE-speciﬁc, both include elements of UE function
[26–28]. Both have a similar underlying approach to scal-
ing, which is to assess speciﬁc neurological (SCAR) and
functional activities (SCAR and SCI-FI) along a continuum
of increasing difﬁculty.
The SCI-FI is a PRO-based tool that is available as a
computer adaptive test (CAT) and short form to capture
individual performance of physical function [26, 27, 29].
CAT ﬁrst presents an item in the middle of the range of
difﬁculty (not too hard, not too easy) and uses the response
to estimate ability and determine the next appropriate item
to present. This process continues until a predeﬁned preci-
sion is met or a predeﬁned stop-rule (e.g., stop at 5-items, or
10-items) is reached. The SCI-FI was developed as a PRO
with the goal of including comprehensive content to cover
all aspects of physical function in ﬁve-item banks (basic
mobility, ambulation, wheelchair mobility, self-care, and
ﬁne motor function) while incorporating the perspective of
individuals living with SCI across the full range of SCI
severity and level of injury [26]. Self-care and ﬁne motor
item banks are the most relevant to the assessment of UE
function. The tool was developed using item response the-
ory, which is a conceptual model for design, analysis, and
scoring of instruments that is intended to measure abilities
or traits. The statistical procedure calibrates (or aligns) the
items in the bank according to difﬁculty and discrimin-
ability parameters.
Precision is achieved by using item response theory
calibrations, which, when administered by CAT, minimizes
the likelihood of administering irrelevant items. For exam-
ple, if an individual is not able to write with a pen or a
L. A. T. Jones et al.
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pencil, items related to more difﬁcult tasks (e.g., picking up
a coin from the ground) would not be administered. CAT
administration is tailored to subject ability and provides an
estimation of function, achieving precision with reduced
subject burden. Capacity measures (e.g., functional inde-
pendence measure and SCIM) with a limited number of
observable items may not adequately identify discrete
changes in function due to gaps in content.
Like all PROs, experience performing the activities and
an individual’s knowledge of their functional limitations are
needed for accurate reporting. Thus, the SCI-FI is poten-
tially a good measure of change in performance when used
at relatively chronic time points after injury. Consideration
should be given to a complementary capacity assessment
(by observation in the clinic) using the concepts of CAT,
namely that the activities assessed are tailored and appro-
priate to an individual’s level of function.
Traditionally, many of the COA tools used in SCI are
ordinal, or rank ordered, but the intervals between rankings
are either unknown, unequal, or highly variable. For
example, improvement from an ISNCSCI segmental motor
score of 0–1 (0= total paralysis, 1= palpable or visible
contraction) does not imply the same degree of improve-
ment as a change from 3 to 4 (3= active movement, full
range of motion against gravity alone, 4= active move-
ment, full range of motion against gravity and moderate
resistance). Moreover, the numerical changes in one muscle
group are not necessarily functionally equivalent to the
same changes in a different group, which are then combined
to create a total score. The use of such ordinal measures
limits the type, accuracy, and strength of the statistical
analyses that can be applied and creates challenges in
interpreting signiﬁcant outcomes across a spectrum of
impairment and functional deﬁcits.
The SCAR is a new capacity-based assessment described
as a measure of “volitional performance” developed to
address challenges with ordinal measures [28]. Volitional
performance is deﬁned as voluntary task-speciﬁc physical
actions contributing to independence in activities of daily
living (ADLs), e.g., speciﬁc SCIM III items associated with
voluntary movement. SCAR is designed to inclusively
measure recovery across the entire range of severity and
level of injury. It combines aspects of volitional perfor-
mance (function) with strength (impairment), a key con-
tributor to volitional performance. As SCAR contains
elements of impairment and function, one may assess
recovery vs. behavioral compensation over time. For
example, an individual with improved mobility due to
compensation alone will have a lower score than an indi-
vidual with improved strength and mobility, reﬂecting
recovery. The SCAR relies on select items from commonly
used ordinal assessments (ISNCSCI and SCIM III), which
are converted to a linear measure of volitional performance
(Rasch analysis). Psychometric properties of the SCAR
were tested and validated using Rasch analysis (retro-
spective modeling), and were found to be linear, interval
measures with a meaningful total score that reﬂects changes
in functional recovery [28].
As mentioned above, one issue identiﬁed with current
functional assessment tools (e.g., SCI-FI and SCIM III) is
that they are difﬁcult to complete at early time points after
injury, whereas it is possible to collect neurological
impairment measures (ISNCSCI motor scores) within hours
following SCI. When SCAR is utilized in an acute SCI trial,
the ISNCSCI component of the measure can be collected at
the earliest time points and utilized to estimate recovery by
Rasch modeling. As an interval measure, the SCAR pro-
vides meaningful scores across the continuum of severity
and level of injury, however, further testing and validation
of this measure is required.
For established and emerging measures used in clinical
trials that assess a single underlying construct, Rasch ana-
lysis or similar methods should be considered. While not
the focus of this article, a thorough discussion of the
rationale for assessing and/or creating linear interval level
COAs is addressed by Steeves et al. [28].
Remaining gaps and options to address recruitment
As with most neurological conditions, recruitment to SCI
trials is challenging, particularly at acute and subacute time
points. Although the incidence of SCI in the United States is
~17,000 per year, patients are dispersed among numerous
level I and II trauma centers [1]. Once trial inclusion/
exclusion criteria are applied, the number of individuals
who are eligible for and consent to participate in clinical
trials often becomes low. In addition, SCI is heterogeneous,
with varying levels and severities of injury and a high rate
of concomitant injuries. Due to these factors and others,
there is a “funnel” effect in clinical trial recruitment leading
to an extended time frame for the completion of a clinical
trial (e.g., due to slow recruitment), resulting in increased
costs and decreased enthusiasm on the part of trial sponsors.
Traditionally, SCI clinical trials have been completed in a
methodical, sequential fashion as they progressed from
complete thoracic SCI participants to either thoracic
incomplete or cervical complete to cervical incomplete.
Although safety studies in a limited SCI thoracic population
may be necessary during early phase safety trials of high-risk
interventions, the ability to inclusively recruit and simulta-
neously enroll a broad range of cervical and thoracic complete
and incomplete SCI participants in mid- and late-phase trials,
would improve trial efﬁciency. Newer statistical designs and
alternative clinical trial methodologies, such as adaptive trial
designs, may facilitate more streamlined enrollment.
Considerations and recommendations for selection
Prognostic modeling may be used to prospectively stra-
tify initially heterogeneous populations into homogeneous
study cohorts based on identiﬁcation of those baseline
clinical characteristics that signiﬁcantly predict a future
clinical end point. Such modeling techniques may facilitate
inclusive enrollment of parallel vs. sequential cohorts, thus
decreasing the overall clinical trial duration. One method of
prognostic modeling recently used in SCI is unbiased
recursive partitioning, a type of regression analysis [30, 31].
The desired clinical end point is chosen by the investigator;
unbiased recursive partitioning is then used to determine
which early clinical factors (e.g., ISNCSCI motor scores,
SCIM) signiﬁcantly contribute to the end point of choice.
Participants are then stratiﬁed (split) into homogeneous
groups based on the combinations of the early (baseline)
predictors. Unbiased recursive partitioning has been tested
in both cervical complete and incomplete SCI models as a
means to be “inclusive” in trial recruitment while identifying
individuals who should be excluded due to ceiling or ﬂoor
effects. Validation against multiple SCI databases and
against established statistical approaches has been under-
taken [31]. Once the predictive models have been gener-
ated, the investigator can determine which groups (based on
the baseline assessment) should be enrolled in the study and
determine appropriate target outcomes. Prospective model-
ing approaches hold promise to appropriately broaden trial
participant inclusion, as well as identify applicable out-
comes for comparable homogenous cohorts.
Adaptive trial design may be one way to address the
challenges associated with recruitment, and should be
considered in the context of enrollment and clinical trial
progression in order to ﬁnd the “most direct route to a sta-
tistically signiﬁcant result using the smallest number of
subjects” [32]. Adaptive trial design allows for modiﬁcation
of a trial based on incoming data without impacting the
validity of the trial. Preset conditions are designated where
modiﬁcations to dose, sample size, or eligibility criteria may
occur based on the analysis of an early subset of the data.
For example, in drug-dosing studies, ﬁve dosing arms may
be initiated simultaneously. In a traditional dose ﬁnding
study, subjects may be enrolled in doses sequentially or in
parallel with a predetermined sample size per group.
Adaptive trial design may allow an investigator to stop
enrolling in non-efﬁcacious doses, while continuing with
more promising doses, thus, saving time and minimizing
subject exposure to potential risks. The conditions and
decision points are preset, which may lead to a longer
period for trial design and setup, but a more efﬁcient overall
clinical trial timeline.
Results from prior adaptive or traditional trial designs
may also be used to determine trial eligibility criteria. Based
on data accumulated in early stage trials, an aggregate score
for inclusion may be indicated. Those participants who
score above a certain threshold may be recruited, whereas
those with scores below would not be recruited as they are
least likely to demonstrate improvement. Not only does this
approach streamline enrollment, it also minimizes exposure
to unproven therapeutics in individuals who are unlikely to
beneﬁt. For example, older individuals with SCI may not
recover as well as younger individuals, which may vary
depending on the severity of SCI [33]. Additional surrogate
markers such as severity of injury based on magnetic
resonance imaging may also factor into an aggregate cutoff
score. Combining information gained from prognostic
modeling using large cohorts and early phase studies to
develop “cutoff” scores for trial inclusion could be
beneﬁcial.
Conclusion
Optimizing UE function following SCI is essential to
enhance independence in ADLs leading to improved quality
of life. As clinical trials related to drugs and biologic
intervention emerge, there is great need for valid and sen-
sitive COAs that capture improvement in function. In recent
years, the ﬁeld of SCI has matured with the development of
SCI-speciﬁc COAs, some of which are tailored to assess UE
function, others that are more inclusive in their coverage,
allowing assessment of upper and lower extremity function.
In selecting COAs for a clinical trial, many factors, such as
showing evidence of recovery and the ability to demonstrate
clinically meaningful change, need to be considered at the
trial development stage. Emerging methods for inclusive
COAs measures, prognostic modeling, patient stratiﬁcation,
and adaptive trial designs are likely to improve SCI study
efﬁciency and should be further validated in the clinical trial
setting. The continued understanding and development of
existing measures ensures the ﬁeld of SCI research will be
well positioned to assess the efﬁcacy of emerging inter-
ventions and the impact on UE function.
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